Key Performance
More- Earnings Score: N/A
- Momentum Score: 36
- True Yield: N/A
- Financial Health Score: N/A
%20scale(1,1)}%2025%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.85,0.85)}%2050%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.7,0.7)}%2075%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.85,0.85)}%20100%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(1,1)}}%20%23ewMkZ6d8Hun3_ts%20{animation:%20ewMkZ6d8Hun3_ts__ts%204000ms%20linear%20infinite%20normal%20forwards}@keyframes%20ewMkZ6d8Hun3_ts__ts%20{%200%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(1,1)}%2025%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.85,0.85)}%2050%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.7,0.7)}%2075%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.85,0.85)}%20100%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(1,1)}}%20]]%3e%3c/style%3e%3cdefs%3e%3clinearGradient%20id='ewMkZ6d8Hun2-fill'%20x1='12.5'%20y1='23.5001'%20x2='-0.868518'%20y2='16.4047'%20spreadMethod='pad'%20gradientUnits='userSpaceOnUse'%20gradientTransform='translate(0%200)'%3e%3cstop%20id='ewMkZ6d8Hun2-fill-0'%20offset='0%25'%20stop-color='%23FF2F00'/%3e%3cstop%20id='ewMkZ6d8Hun2-fill-1'%20offset='100%25'%20stop-color='%23FF9100'/%3e%3c/linearGradient%3e%3clinearGradient%20id='ewMkZ6d8Hun3-fill'%20x1='31.5059'%20y1='27.1026'%20x2='10.2884'%20y2='14.9373'%20spreadMethod='pad'%20gradientUnits='userSpaceOnUse'%20gradientTransform='translate(0%200)'%3e%3cstop%20id='ewMkZ6d8Hun3-fill-0'%20offset='4.7%25'%20stop-color='%23FF2F00'/%3e%3cstop%20id='ewMkZ6d8Hun3-fill-1'%20offset='100%25'%20stop-color='%23FF9100'/%3e%3c/linearGradient%3e%3c/defs%3e%3cg%20id='ewMkZ6d8Hun2_ts'%20transform='translate(24.943161,19.954806)%20scale(1,1)'%3e%3cpath%20d='M14.8466,29.2814c0,0-14.408088-4.6983-12.05895-19.79995c0,0,1.50345,4.85085,4.13448,5.30845s-2.03592,4.6373,7.92447,14.4915Z'%20transform='translate(-24.943161,-19.954806)'%20fill='url(%23ewMkZ6d8Hun2-fill)'/%3e%3c/g%3e%3cg%20id='ewMkZ6d8Hun3_ts'%20transform='translate(24.9787,20.012362)%20scale(1,1)'%3e%3cpath%20d='M37.4922,21.9282l4.0719.244v-12.81353C31.0713,3.28748,17.7595,7.6502,17.7595,7.6502c.3445-4.51526-3.5707-5.52204-3.5707-5.52204c2.5371,1.52542.3132,6.22373.3132,6.22373C13.0299,0.084092,0,1.02986,0,1.02986C8.92672,4.35528,6.70287,7.98579,6.8908,16.6197c.18794,8.6034,8.3943,12.9966,8.3943,12.9966l-6.60895-.2441v13.2407c0,0,5.48135,2.3797,13.68765,3.1729v-22.3017h-4.4477c-1.0023,0-1.942-.8237-1.942-1.8v-5.7356c0-.9763.9397-1.8,1.942-1.8h4.4477v-1.3424h5.0115v1.3424h5.0115c1.0023,0,1.848.7932,1.848,1.8v5.7356c0,.9763-.8144,1.8-1.848,1.8h-5.0115v22.5153h.2819c11.1192-.0611,15.9428-7.3221,16.256-13.3017.4698-7.7492-6.421-10.7695-6.421-10.7695Z'%20transform='translate(-24.9787,-20.012361)'%20fill='url(%23ewMkZ6d8Hun3-fill)'/%3e%3c/g%3e%3c/svg%3e)
Latest Research & News
Quantum BioPharma Provides Corporate Update
Quantum BioPharma announced that its Lucid-MS (Lucid-21-302) investigational drug for multiple sclerosis treatment has been placed on clinical hold by the FDA pending submission of additional information. The company believes the issues are addressable and plans to submit a response package. Previously disclosed timelines for FDA review, Phase 2 trial initiation, and data milestones have been withdrawn. Additionally, Dr. Lakshmi P. Kotra resigned as director but will remain as a senior clinical advisor.
06/01/2026, 7:30 PM • GlobeNewswire
Quantum BioPharma Provides Corporate Update
Quantum BioPharma has engaged two marketing firms—Senergy Communications Capital Inc. and King Tide Media LLC—to provide marketing and investor awareness services starting May 2026. The company will pay USD $150,000 to Senergy and USD $125,000 to KTM for corporate branding, social media, and advertising initiatives on one-month contracts with renewal options.
04/27/2026, 7:45 PM • GlobeNewswire
Quantum Biopharma Provides Corporate Update
Quantum BioPharma Ltd. granted 35,000 stock options to employees and consultants, exercisable at CA$6.50 for five years. The options vest immediately and are subject to a four-month hold period. The grant was made under the company's shareholder-approved stock option plan.
03/27/2026, 7:30 PM • GlobeNewswire
Quantum Biopharma Announces Closing of Initial Tranche of Private Placement Offering
Quantum BioPharma Ltd. has closed the first tranche of its debenture unit offering, raising $3.75 million CAD from 3,750 Debenture Units. The company also completed an initial batch of debt settlement by issuing 370,457 Class B subordinate voting shares to settle approximately $1.12 million CAD of debt owed to creditors and insiders. Proceeds will be used for business development and working capital.
03/20/2026, 7:35 PM • GlobeNewswire
Quantum BioPharma Provides Corporate Update
Quantum BioPharma Ltd. announced revised terms for its Debenture Units offering following a decrease in its Class B subordinate voting share price. The company reduced the conversion price per share to $3.00, increased warrant allocation to 333.33 per unit, and lowered the exercise price per warrant share to $3.75. The debt settlement will also be completed at the reduced conversion price.
03/11/2026, 7:55 PM • GlobeNewswire
Quantum BioPharma Provides Corporate Update
Quantum BioPharma announced a non-brokered private placement offering of up to 4,000 convertible debenture units at $1,000 each, with 1.25% monthly interest and a 24-month maturity. The company also plans to settle creditor and insider debts through share issuance at $4.00 per share. Proceeds will support business development and working capital.
03/10/2026, 7:45 PM • GlobeNewswire
A class action lawsuit has been filed against Canadian Imperial Bank of Commerce (CIBC) and Royal Bank of Canada (RBC) alleging they engaged in market manipulation by placing spoofed sell orders to artificially deflate Quantum Biopharma Ltd. stock prices, then purchasing shares at depressed levels for profit. Investors who sold Quantum securities between January 6, 2021 and October 15, 2025 are encouraged to join the case.
02/19/2026, 12:00 PM • GlobeNewswire
Portnoy Law Firm Announces Class Action on Behalf of Quantum Biopharma, Ltd. Investors
The Portnoy Law Firm has filed a class action lawsuit on behalf of Quantum Biopharma investors who purchased securities between January 6, 2021 and October 15, 2025. The complaint alleges that defendants engaged in stock price manipulation through spoofed sell orders designed to artificially depress the stock price, allowing them to purchase shares at deflated levels while deceiving investors into selling at artificially low prices.
02/17/2026, 1:55 PM • GlobeNewswire
Pomerantz Law Firm has filed class action lawsuits against Quantum Biopharma Ltd. and other companies for alleged securities fraud and market manipulation. The complaint alleges that CIBC World Markets, RBC Dominion Securities, and Royal Bank of Canada engaged in spoofed sell orders to artificially depress Quantum's stock price, allowing them to purchase shares at depressed levels while deceiving other investors.
02/17/2026, 12:59 PM • GlobeNewswire
A class action lawsuit has been filed against Canadian Imperial Bank of Commerce (CIBC) and Royal Bank of Canada (RBC) alleging they engaged in spoofing and market manipulation schemes to artificially deflate the price of Quantum Biopharma Ltd. securities between January 2021 and October 2025. The defendants allegedly placed thousands of false sell orders to deceive investors into selling shares at depressed prices, then purchased shares at these artificially low levels for profit. Investors who sold Quantum shares during the class period are encouraged to join the lawsuit.
02/12/2026, 12:00 PM • GlobeNewswire
Portnoy Law Firm Announces Class Action on Behalf of Quantum Biopharma Ltd. Investors
The Portnoy Law Firm has announced a class action lawsuit on behalf of Quantum Biopharma Ltd. investors who purchased securities between January 6, 2021 and October 15, 2025. The complaint alleges that defendants engaged in market manipulation through spoofed sell orders designed to artificially depress the stock price, enabling them to purchase shares at deflated levels while deceiving investors into selling at artificially low prices.
02/02/2026, 10:46 AM • GlobeNewswire
A class action lawsuit has been filed against Canadian Imperial Bank of Commerce (CIBC) and Royal Bank of Canada (RBC) for allegedly executing manipulative trades designed to artificially deflate the stock price of Quantum Biopharma Ltd. The defendants allegedly placed spoofed sell orders to deceive investors into selling shares at artificially depressed prices, which they then purchased at the lower levels. The class period covers January 6, 2021 to October 15, 2025, and investors have until February 23, 2026 to request lead plaintiff status.
01/29/2026, 12:00 PM • GlobeNewswire
Pomerantz Law Firm has filed class action lawsuits against Quantum Biopharma Ltd. and other companies for alleged securities fraud. The complaint alleges that CIBC World Markets, RBC Dominion Securities, and Royal Bank of Canada engaged in spoofed sell orders to artificially depress Quantum's stock price, allowing them to purchase shares at depressed levels while deceiving other investors into selling at artificially low prices. The deadline to join as Lead Plaintiff is February 23, 2026.
01/27/2026, 1:42 PM • GlobeNewswire
Quantum BioPharma announced completion of oral dosing in 180-day repeated dose toxicity and toxicokinetic studies for Lucid-21-302 (Lucid-MS), a first-in-class treatment candidate for multiple sclerosis. The studies will support the company's Investigational New Drug (IND) application with the US FDA and inform the design of a Phase 2 trial. Lucid-MS is designed to prevent myelin degradation and disease progression in MS patients.
12/23/2025, 8:00 AM • GlobeNewswire
Law firm Grant & Eisenhofer has filed a class action lawsuit alleging that Canadian banks CIBC and RBC engaged in illegal stock market manipulation of Quantum BioPharma shares between January 2021 and October 2025. Quantum BioPharma intends to seek appointment as lead plaintiff to protect shareholders. The case has garnered media attention from CTV News' investigative program W5.
12/19/2025, 4:52 PM • GlobeNewswire
Peers
Statistics
MoreInformation as of 06/03/2026
Company Profile
Quantum BioPharma Ltd., together with its subsidiaries, operates as a biopharmaceutical company. The company operates through two segments, Biopharmaceutical Innovation and Strategic Investments. It researches and develops a portfolio of assets and biotech solutions for the treatment of neurodegenerative, inflammatory and metabolic disorders, and alcohol misuse disorders with drug candidates in different stages of development. The company's lead compound is Lucid-MS, a patented new chemical entity that is in Phase 2 clinical trial to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. It also develops FSD-PEA, which is in preparation for Phase 2 trial for the treatment of inflammatory diseases, such as mast cell activation syndrome; Lucid-PSYCH to treat major depressive disorder; and unbuzzd, a dietary supplement for the treatment of alcohol misuse. In addition, the company maintains a portfolio of strategic investments comprising loans secured by residential property. The company was formerly known as FSD Pharma Inc. and changed its name to Quantum BioPharma Ltd., in August 2024. Quantum BioPharma Ltd. was founded in 1998 and is based in Toronto, Canada.